Compare Quest Diagnostics Inc (DGX) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs The Coca-Cola Co K — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while The Coca-Cola Co K trades at $83.21 (market cap $357.45B). The key difference: The Coca-Cola Co K is far larger — about 15.7× Quest Diagnostics Inc's market cap, and The Coca-Cola Co K pays the higher dividend (2.55%). Which is the better fit depends on your goals.
| DGX | KO | |
|---|---|---|
Market Cap | $22.80B | $357.45B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $84.25 |
52-Week Low | $166.42 | $65.67 |
Enterprise Value | $28.82B | $387.52B |
Dividend Yield | 1.67% | 2.55% |
Volume | — | 14,630,257 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Coca-Cola (KO) trades at $84.25, up 0.91% today, with a bullish technical outlook and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.86 exceeding expectations. Revenue grew to $47.94B in 2025, with a robust net income margin of 27.8%. Analyst consensus is bullish with a $89.75 price target, and institutional buying activity is notable, supporting positive sentiment.
The outlook for KO remains favorable due to steady dividend growth, strong profitability, and global brand strength. Key risks include regional demand volatility and high debt levels. Investors may find value in its consistent earnings performance and analyst upside, though macroeconomic pressures could pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
